VEGFA and retinopathy of prematurity: A number of studies, such as the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity study (BEAT-ROP study), has confirmed the efficacy of anti-VEGF agents in ROP treatment [bevacizumab (IVB) (18–21); ranibizumab (IVR) (22–24); conbercept (IVC) (25–27)].